NR4A1 and breast carcinoma: While AIs are a key treatment for postmenopausal women with hormone receptor‐positive early‐stage breast cancer, the development of joint pain and muscle stiffness limits patients' quality of life and compliance with therapy, highlighting the need for effective treatment strategies [1, 3, 7, 31, 32].